<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742973</url>
  </required_header>
  <id_info>
    <org_study_id>17039</org_study_id>
    <secondary_id>I4V-MC-JAIV</secondary_id>
    <nct_id>NCT03742973</nct_id>
  </id_info>
  <brief_title>A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and efficacy of baricitinib in participants with primary
      biliary cholangitis (PBC) who do not respond or are unable to take ursodeoxycholic acid
      (UDCA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Actual">September 26, 2019</completion_date>
  <primary_completion_date type="Actual">September 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Alkaline Phosphatase (ALP)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in ALP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with ALP&lt;1.67 x Upper Limit of Normal (ULN) (and at Least 15% Decrease from Baseline) and Total Bilirubin &lt; ULN</measure>
    <time_frame>Week 12</time_frame>
    <description>Proportion of participants with ALP&lt;1.67 x ULN (and at least 15% decrease from baseline) and total bilirubin &lt; ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Itch Numeric Rating Scale (NRS)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in itch NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fatigue NRS</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Change from baseline in fatigue NRS</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>Baricitinib Low Dose Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Baricitinib High Dose Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baricitinib administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Cohort B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Baricitinib</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Baricitinib High Dose Cohort B</arm_group_label>
    <arm_group_label>Baricitinib Low Dose Cohort A</arm_group_label>
    <other_name>LY3009104</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo Cohort A</arm_group_label>
    <arm_group_label>Placebo Cohort B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of PBC (consistent with American Association for the Study of Liver
             Disease [AASLD] and European Association for Study of the Liver [EASL] Practice
             Guidelines; as demonstrated by the presence of at least 2 of the following 3
             diagnostic factors:

               -  History of elevated ALP levels for at least 6 months

               -  Positive antimitochondrial antibodies titer

               -  Liver biopsy consistent with PBC

          -  Have ALP ≥1.67 x ULN but &lt;6 x ULN.

          -  Taking UDCA for at least 52 weeks (stable dose for at least 12 weeks) prior to Week 0,
             or have previously taken, but are intolerant (in the opinion of the investigator) to
             UDCA and have not received UDCA for at least 12 weeks prior to Week 0.

          -  Nonpregnant, nonbreastfeeding female participants of childbearing potential.

        Exclusion Criteria:

          -  History or presence of other concomitant liver diseases including:

               -  Hepatitis C virus (HCV) infection

               -  Hepatitis B virus (HBV) infection

               -  Primary sclerosing cholangitis

               -  Alcoholic liver disease

               -  Autoimmune liver disease other than PBC, such as overlap hepatitis

               -  Nonalcoholic steatohepatitis

               -  Gilbert's syndrome

          -  Presence of clinical complications of PBC or clinically significant hepatic
             decompensation, including:

               -  Liver transplantation, current placement on a liver transplant list or current
                  Model for End Stage Liver Disease (MELD) score ≥15

               -  Portal hypertension with complications, including known gastric or esophageal
                  varices, ascites, history of variceal bleeds or related therapeutic or
                  prophylactic interventions (e.g., beta blockers, insertion of variceal bands or
                  transjugular intrahepatic portosystemic shunt), or hepatic encephalopathy

               -  Cirrhosis, including history or presence of one or more of the following:

                    -  spontaneous bacterial peritonitis

                    -  hepatocellular carcinoma

               -  Hepatorenal syndrome (type I or II)

          -  Have an estimated glomerular filtration rate (eGFR) based on the most recent available
             serum creatinine of &lt;90 milliliters/minute/1.73 m2.

          -  Have screening electrocardiogram (ECG) abnormalities that in the opinion of the
             investigator or the sponsor are clinically significant and indicate an unacceptable
             risk for the participant's participation in the study.

          -  Have experienced any of the following within 12 weeks of screening: myocardial
             infarction, unstable ischemic heart disease, stroke, or New York Heart Association
             Stage III/IV heart failure.

          -  Have a history of venous thromboembolism (VTE) (deep vein thrombosis/pulmonary
             embolism [DVT/PE]).

          -  Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
             endocrine, hematological, neurological, or neuropsychiatric disorders or any other
             serious and/or unstable illness that, in the opinion of the investigator, could
             constitute an unacceptable risk when taking investigational product or interfere with
             the interpretation of data.

          -  Have a current or recent (&lt;4 weeks prior to randomization) clinically serious
             infection or any other active or recent infection that, in the opinion of the
             investigator, would pose an unacceptable risk to the participant if participating in
             the study.

          -  Have had symptomatic herpes zoster infection within 12 weeks prior to randomization.

          -  Have active tuberculosis (TB) disease determined on the basis of a positive medical
             history, physical examination, or chest radiography (per local standard of care) or
             latent TB infection (LTBI).

          -  Have any of the following specific abnormalities based on screening central lab test
             results:

               -  Hemoglobin &lt;10 grams per deciliter (100.0 grams per liter)

               -  Alanine aminotransferase (ALT) &gt;3 x ULN

               -  aspartate aminotransferase (AST) &gt;3 x ULN

               -  alkaline phosphatase (ALP) &gt;6 x ULN

               -  Total bilirubin level (TBL) &gt;ULN

               -  Creatine phosphokinase (CPK) &gt; ULN

               -  Serum albumin &lt; lower limit of normal (LLN)

               -  International Normalized Ratio of Prothrombin Time (INR) &gt; ULN

               -  Total white blood cell (WBC) count &lt;LLN

               -  Absolute neutrophil count [ANC] &lt;LLN

               -  Lymphocyte count &lt;LLN

               -  Platelet (thrombocyte) count &lt;LLN

          -  Are receiving unstable treatment for pruritus within 6 weeks prior to Week 0.

          -  Have been treated with systemic (oral or parenteral) corticosteroids within 6 weeks
             prior to Week 0.

          -  Have received biologic treatments for an immunologic disease within 4 weeks of
             screening.

          -  Have received a Janus kinase (JAK) inhibitor.

          -  Have received obeticholic acid.

          -  Have received fenofibrate or other fibrates for the treatment of PBC.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California GI and Liver Centers (SCLC)</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis - Health Systems</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Diseases/University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Digestive Health and Liver Disease at Mercy</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UH Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinical Investigations Group, LLC</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico, Medical Sciences Campus</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies#?conditions=3xVpJX9qE0UUC2c86gmUsu</url>
    <description>Click here for more information about this study: A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>October 19, 2019</last_update_submitted>
  <last_update_submitted_qc>October 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Janus kinase inhibitor</keyword>
  <keyword>JAK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

